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Induced pluripotent stem cells (iPSCs) hold great
promise for personalized regenerative medicine.
However, recent studies show that iPSC lines carry
genetic abnormalities, suggesting that reprogram-
ming may be mutagenic. Here, we show that the
ectopic expression of reprogramming factors in-
creases the level of phosphorylated histone H2AX,
one of the earliest cellular responses to DNA
double-strand breaks (DSBs). Additional mecha-
nistic studies uncover a direct role of the homolo-
gous recombination (HR) pathway, a pathway
essential for error-free repair of DNA DSBs, in re-
programming. This role is independent of the use of
integrative or nonintegrative methods in introducing
reprogramming factors, despite the latter being con-
sidered a safer approach that circumvents genetic
modifications. Finally, deletion of the tumor sup-
pressor p53 rescues the reprogramming phenotype
in HR-deficient cells primarily through the restoration
of reprogramming-dependent defects in cell prolifer-
ation and apoptosis. These mechanistic insights
have important implications for the design of safer
approaches to creating iPSCs.INTRODUCTION
Pioneering work by Yamanaka and colleagues has identified key
transcription factors that enable the reprogramming of somatic
cells to a pluripotent state (Takahashi and Yamanaka, 2006).
This technology has been used to generate human induced
pluripotent stem cells (iPSCs), which closely resemble embry-
onic stem cells (ESCs) in terms of differentiation potential, self-
renewal capacity, transcriptional profile, and epigenetic state
(Hochedlinger and Plath, 2009; Okita and Yamanaka, 2011).
Like ESCs, iPSCs can be differentiated into a wide range ofcell types, allowing the generation of patient-specific cells suit-
able for cell-replacement therapy and disease modeling.
Despite this great promise, a number of studies suggest that
reprogramming and the subsequent expansion of iPSCs in
culture lead to the accumulation of diverse genetic abnormalities
at chromosomal, subchromosomal, and nucleotide levels (Gore
et al., 2011; Hussein et al., 2011; Laurent et al., 2011; Mayshar
et al., 2010). The source of these genetic lesions remains under
debate. Some reports attribute them primarily to clonal capture
of variant cells within the donor cell population (Cheng et al.,
2012; Young et al., 2012), yet another study suggests that
approximately half of the mutations arise de novo during reprog-
ramming (Gore et al., 2011). This has prompted us to examine
the roles of the homologous recombination (HR) DNA repair
pathway in reprogramming and whether reprogramming is a
trigger of DNA damage.
We used a drug-inducible system to discriminate the effects
of reprogramming from viral integration, because the latter is
known to cause DNA double-strand breaks (DSBs). The results
show that the ectopic expression of reprogramming factors is
sufficient to induce DNA DSBs, providing a plausible molecular
mechanism for genetic abnormalities observed in iPSC lines.
Furthermore, efficient reprogramming requires key HR genes,
including Brca1, Brca2, and Rad51, independently of the
methods used to introduce reprogramming factors. Finally,
deletion of the tumor suppressor p53 largely restores normal re-
programming in HR-deficient mouse embryonic fibroblasts
(MEFs), accompanied by a correction of reprogramming-depen-
dent defects in cell proliferation and apoptosis. These findings
provide important mechanistic insights into reprogramming and
have important implications for designing rational approaches
for the generation of lesion-free iPSCs suitable for clinical
applications.RESULTS
Reprogramming Induces DSBs
DNA DSBs can be triggered by a number of DNA-damaging
agents, such as g-irradiation and oxidative stress. ExcessiveCell Reports 3, 651–660, March 28, 2013 ª2013 The Authors 651
Figure 1. Reprogramming Induces DSBs
and Apoptosis
(A) Representative fluorescence-activated cell
sorting (FACS) plots of 4F- and 3F-infected wild-
type MEFs stained for gH2AX, SSEA1, and
Annexin V after cells were cultured with or without
doxycycline (DOX) for 5 days. Numbers indicate
percentages of positive cells. PI, propidium iodide;
DAPI, 4’6-diamidino-2-phenylindole; L, alive; EA,
early apoptotic; LA, late apoptotic; N, necrotic.
(B) Quantification of the percentage of gH2AX+
cells in wild-type MEFs infected with reprogram-
ming genes in combination or individually. OS,
Oct4-Sox2; O, Oct4; S, Sox2; K, Klf4; M, c-Myc.
(C and D) Quantification of the percentage of
SSEA1+ (C) and Annexin V+ (D) cells in wild-type
MEFs transduced with 4F and 3F. Apoptotic cells
are the sum of EA and LA cells.
(E) Time-lapse flow cytometric quantification of
gH2AX+ cells present in reprogrammable MEFs
with or without DOX treatment; cells were sepa-
rated based on expression of SSEA1. In all column
graphs of this study, error bars indicate SEM and
p values by two-tailed Student’s t test. *, p < 0.05;
**, p < 0.01; ***, p < 0.001; and ****, p < 0.0001,
respectively.accumulation of DSBs in a cell leads to growth arrest, apoptosis,
or mutations in the genome. Ectopic expression of the reprog-
ramming factors Oct4, Sox2, Klf4, and c-Myc or Oct4, Sox2,
and Klf4 (hereafter referred to as 4F or 3F, respectively) allows
the reprogramming of MEFs to a pluripotent state (Hochedlinger
and Plath, 2009; Okita and Yamanaka, 2011). Transduction of 4F
or 3F with constitutive retroviral expression vectors has been
shown to increase the number of cells with phosphorylated
histone H2AX (gH2AX) nuclear foci, one of the earliest cellular652 Cell Reports 3, 651–660, March 28, 2013 ª2013 The Authorsresponses to DSBs (Kawamura et al.,
2009; Mu¨ller et al., 2012). However, it is
unclear whether DSBs are caused by re-
programming or by viral transgene inte-
gration, given that the latter is known to
cause DSBs (Skalka and Katz, 2005).
To determine whether there is a direct
link between epigenetic reprogramming
and increased DNADSBs, we used doxy-
cycline-inducible lentiviral vectors (FUW-
tetO) to express reprogramming factors
in wild-type (WT) MEFs and assessed
gH2AX through flow cytometry (Huang
and Darzynkiewicz, 2006). The effects of
reprogramming genes were determined
by comparing infected cells within the
same pool with or without doxycycline
treatment. We found that 4F- and 3F-in-
fected MEFs showed a 6-fold and a
3-fold increase, respectively, of gH2AX+
cells after 5 days of doxycycline treat-
ment in comparison to infected-but-
untreated or noninfected MEFs, whereasdoxycycline treatment alone on noninfected MEFs had no effect
(Figures 1A and 1B). This correlated with the acquisition of an
early reprogramming marker (SSEA1) and a marked increase in
the percentage of cells undergoing apoptosis, as identified by
Annexin V staining (Figures 1A, 1C, and 1D). Expressing c-Myc
alone also had an effect, consistent with a previous report (Karls-
son et al., 2003), whereas expressing other reprogramming
factors individually or in combination (Oct4 and Sox2) had no
significant effect (Figure 1B).
Because nonintegrative methods are thought to generate
safer iPSCs for clinical use, we measured gH2AX+ cells during
reprogramming using a nonintegrative approach that was based
on the use of ‘‘reprogrammable’’ MEFs (Carey et al., 2010; Stadt-
feld et al., 2010). We generated reprogrammable MEFs by
combining an allele constitutively expressing the reverse tetracy-
cline-controlled transactivator (rtTA) from the Rosa26 locus with
a doxycycline-inducible polycistronic reprogramming cassette
(OKSM) targeted to the Col1A1 locus (Stadtfeld et al., 2010).
This system allows homogeneous expression of the reprogram-
ming factors ideal for studies of reprogramming. Using flow
cytometry, we analyzed the percentage of gH2AX+ cells at dif-
ferent time points after doxycycline treatment. Additionally, we
used the pluripotency cell surfacemarker SSEA1 to identify early
reprogramming cells in doxycycline-treated conditions (Bram-
brink et al., 2008). We observed the same low levels of gH2AX
expression in both untreated MEFs and SSEA1 cells in the
doxycycline-treated condition (Figure 1E). In contrast, there
was a significant increase in the percentage of gH2AX+ cells
in the SSEA1+ population in doxycycline-treated cells. This
increase occurred early and remained constant during the re-
programming process. These results demonstrate that reprog-
ramming, rather than viral integration, is directly responsible for
the accumulation of gH2AX in cells.
Reprogramming Is Impaired in Brca1 and Brca2
Mutant MEFs
In mammalian cells, three pathways have been described for the
repair of DSBs: HR, nonhomologous end-joining (NHEJ), and
single-strand annealing (SSA) (Moynahan and Jasin, 2010). HR
is responsible for the accurate repair of DNA damage using the
sister chromatid as a template. In contrast, repairs by NHEJ
and SSA are intrinsically error-prone and can lead to deletions
and other types of mutations. Previous studies have shown
that fibroblasts defective for the Fanconi anemia (FA) comple-
mentation group are resistant to reprogramming through classic
viral-infection-based methods (Mu¨ller et al., 2012; Raya et al.,
2009). These studies suggest a potential link between HR and
reprogramming, given that several FA pathway components
have been shown to promote HR (Nakanishi et al., 2005).
However, a direct role of HR in reprogramming has not been
established because FA proteins also have distinct functions
independent of HR.
We examined the role of Brca1 and Brca2, two genes essen-
tial for homology-directed DNA repair, during reprogramming
using homozygous MEFs generated from three hypomorphic
mutant alleles. Brca1Tr carries an insertion within exon 11,
leading to a truncated Brca1 protein with 924 amino acids (Lud-
wig et al., 2001). The second Brca1 allele, Brca1S1598F, contains
a point mutation in the Brca1 C-terminal domain which disrupts
the interaction of Brca1 with the phosphorylated isoforms of
several repair proteins including, Abraxas (CCDC98), BACH1
(FancJ), and CtIP (Shakya et al., 2011). The Brca2D27 allele
harbors a deletion of exon 27, which generates a truncated
protein lacking 187 C-terminal amino acids (McAllister et al.,
2002). All three mutations impair homology-directed DNA repair.
Adult mice that are homozygous for each of these mutations are
identified from crosses of heterozygous animals, suggestingthat these mutations do not significantly affect cell growth or
survival in vivo.
InWTMEFs, we typically detected300 alkaline phosphatase
(AP)+ colonies and 100 Nanog+ colonies 3 weeks after plating
of 50,000 4F-infected cells using the constitutive retroviral
expression vector pMXs (Figures 2A and 2B). In contrast, the
numbers of AP+ and Nanog+ colonies were significantly reduced
(up to 20-fold) in Brca1 and Brca2 homozygous mutant MEFs
when compared toWT control MEFs (Figures 2B–2D). By picking
colonies with iPSC-like morphology, we were able to establish
Brca2 mutant iPSC lines with comparable efficiency (40%) to
WT controls (Figure S1A). Brca2 mutant iPSCs were indistin-
guishable from control WT iPSCs in expression of Nanog and
other pluripotency markers by real-time quantitative RT-PCR
(qRT-PCR) and immunohistochemical analysis (Figure S1B and
S1D). The rates of proliferation and apoptosis were not signifi-
cantly different between Brca2mutant iPSC lines in comparison
to control WT lines (Figures S1E–S1H). Therefore, the reprog-
ramming phenotypes observed in Brca2 mutant MEFs are not
due to impaired proliferation and/or increased apoptosis of
HR-deficient iPSCs formed during reprogramming. However,
we were not able to establish a bona fide iPSC line from Brca1
mutant MEFs out of the ten colonies picked (Figure S1A). The
best Brca1 mutant lines appeared partially reprogrammed, ex-
hibiting only occasional Nanog staining by immunohistochem-
ical analysis. In comparison to Brca2mutant and WT iPSC lines,
Brca1 mutant lines exhibited limited upregulation of the pluripo-
tency gene Nanog, accompanied by incomplete silencing of the
fibroblast marker Col6a1 and reprogramming transgenes (Fig-
ures S1B–S1D). These data show that both Brca1 and Brca2
are required for efficient reprogramming, and that Brca1 may
also be required for iPSC-line establishment.
Next, we examined whether mutations in Brca1 and Brca2
affect 3F reprogramming without c-Myc, the overexpression of
which alone increases DNA DBSs. Using doxycycline-inducible
lentiviral expression vectors (FUW-tetO) to express 3F, we de-
tected 150 AP+ colonies and 40 Nanog+ colonies 3 weeks
after plating 50,000 infected, doxycycline-treated WT MEFs.
As in 4F reprogramming, both Brca1 and Brca2 homozygous
mutant MEFs showed up to a 20-fold reduction in the number
of AP+ colonies (Figures 2E and 2F). Moreover, no Nanog+ colo-
nies were detected (Figure 2G) frommutant MEFs. These results
support a critical role of Brca1 and Brca2 in both 3F and 4F
reprogramming independent of the infection method used to
introduce reprogramming factors.
Finally, to establish a direct link between reprogramming and
HR-mediated DNA repair, we compared the percentage of
gH2AX+ cells in Brca1Tr/Tr versus WT MEFs during reprogram-
ming (Figure 2H). We detected a significant increase in the
percentage of gH2AX+ cells in both 4F- and 3F-expressing
mutant cells in comparison to WT controls. These data, along
with the established roles of Brca1 and Brca2 in HR, strongly
suggest a direct involvement of HR-mediated DNA DSB repair
in reprogramming.
HR Genes Play a Direct Role during Reprogramming
Brca1 and Brca2 mutant MEFs may have accumulated genetic
or cellular alterations during their culture before reprogramming,Cell Reports 3, 651–660, March 28, 2013 ª2013 The Authors 653
Figure 2. Reprogramming Is Impaired in
Brca1 and Brca2 Mutant MEFs
(A) Schematics of all virus-mediated reprogram-
ming experiments in this study. MEFs were in-
fected with 4F or 3F 1 day after plating and
replated in 12-well dishes the next day on irradi-
ated MEFs at densities specified (indicated below
the AP-staining pictures for all figures in this
study). AP and Nanog staining was performed
after 3 weeks (unless otherwise noted).
(B–D) Representative AP staining (B) and quanti-
fication of AP+ (C) and Nanog+ (D) colonies
generated with 4F reprogramming from Brca1Tr/Tr,
Brca1S1598F/S1598F, and Brca2D27/D27 MEFs in
comparison to wild-type (WT) MEFs from litter-
mate controls.
(E–G) Representative AP staining (E) and quanti-
fication of AP+ (F) and Nanog+ (G) colonies
generated with 3F reprogramming.
(H) Quantification of the percentage of gH2AX+
cells in 4F- and 3F-infected,Brca1Tr/Trmutant, and
control wild-type MEFs after 5 days of DOX
treatment.
See also Figure S1.
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which could prevent the formation of iPSC colonies. Additionally,
mutant MEFs show a small but significant decrease (<3% for
FUW-tetO vectors) in gene-transduction efficiency in compar-
ison to WT controls (Figures S2A and S2B), raising the possibility
that mutant MEFs may reprogram less efficiently because of
a requirement of HR genes for viral integration and transgene
expression. To determine whether HR genes are directly
required for reprogramming, we introduced 4F while simulta-
neously expressing small hairpin RNAs (shRNAs) against indi-
vidual HR genes (Brca1, Brca2, and Rad51) in WT MEFs.
Expectedly, knockdown of HR genes had no significant effect
on the transduction of a GFP reporter or the reprogramming
transgenes (Figures S2C and S2D). Significantly, a decrease in
reprogramming efficiency was observed with all shRNAs except
for one because of insufficient knockdown of the transcript
(Figures 3A–3C and S3D). Themost efficient shRNA (shRad51-b)
reduced the number of AP+ colonies by 60-fold. Likewise,
we performed shRNA-mediated knockdown of Brca1, Brca2,
and Rad51 in 3F reprogramming experiments and observed a
marked decrease of AP+ and Nanog+ colonies (Figures S3A–
S3C and S3E). Similar results were obtained with the use of an
additional pluripotency marker gene, Oct4, by conducting re-
programming experiments on MEFs carrying one copy of the
Oct4-GFP transgenic reporter allele (Szabo´ et al., 2002) (Figures
3D, 3E, S3F, and S3G).
The Requirement of HR Genes Is Independent of Viral
Integration
The experiments described above introduced reprogramming
genes with the use of classic viral-infection-based methods
commonly used in reprogramming studies. However, viral inte-
gration triggers DNA DSBs (Skalka and Katz, 2005), which may
necessitate HR-mediated DNA repair. Therefore, we proceeded
to determine the requirement of HR genes in the absence of viral
infection using reprogrammable MEFs. We infected reprogram-
mable MEFs with shRNAs targeting HR genes and added doxy-
cycline to initiate reprogramming. Using a control shRNA, we
detected, on average, 600 alkaline AP+ colonies (Figures 3D
and 3F) and 500 Nanog+ colonies (Figure 3G) from 50,000 re-
programmable MEFs after 3 weeks of doxycycline treatment.
shRNAs against Brca1, Brca2, and Rad51 all led to a marked
decrease in the number of both AP+ and Nanog+ colonies
(Figures 3D, 3F, 3G, and S3H). These results demonstrate that
DNA damage increases during reprogramming independently
of viral integration and that the HR pathway is also required for
efficient reprogramming through nonintegrative methods.
p53 Deletion Rescues Reprogramming Defects of
HR-Deficient MEFs
Because cells with excessive DNA damage are typically elimi-
nated through p53-dependent apoptosis or growth arrest, we
hypothesized that deletion of p53 would rescue the reprogram-
ming defects in HR-deficient MEFs. This would be consistent
with an established role of the p53 pathway in limiting the rate
of reprogramming (Spike and Wahl, 2011).
We performed 4F reprogramming on MEFs derived from
Brca2 homozygous mutant and WT embryos and used a well-
characterized shRNA to simultaneously suppress p53 (Hemannet al., 2003). Downregulating p53 significantly increased reprog-
ramming efficiency in both mutant and WT MEFs, though the
reprogramming efficiency of mutant MEFs was not rescued to
WT levels (Figures 4A–4C). This partial rescue may be due to
incomplete inactivation of p53 with the knockdown approach
(Figure S4A). To further investigate the role of p53 in HR-defi-
cient MEFs, we generated p53/mutant MEFs (Jacks et al.,
1994) and performed 4F reprogramming experiments while
using shRNAs against Brca1, Brca2, and Rad51. In WT control
MEFs, knockdown of HR genes caused a significant reduction
in the number of AP+ and Nanog+ colonies (Figures 4D–4F and
S4B). A 20-fold increase in the numbers of AP+ and Nanog+
colonies was observed in p53/ mutant MEFs in comparison
to WT control MEFs, consistent with previous reports. However,
knockdown of HR genes generally had no significant effect on
the reprogramming of p53/ mutant MEFs (Figures 4D–4F).
To further investigate the cellular mechanisms, we analyzed
cell proliferation and apoptosis during reprogramming by immu-
nostaining for the mitotic marker phospho-Histone H3 and
the apoptotic marker cleaved Caspase-3. During 4F reprogram-
ming of WT control MEFs, HR deficiency caused a significant
decrease in the percentage of proliferating cells and an increase
of apoptotic cells (Figures 4G, 4H, S4C, and S4D). In contrast,
during 4F reprogramming of p53/ MEFs, HR deficiency failed
to cause any significant defects in cell proliferation or apoptosis
(some increase was observed in apoptosis, though it was not
statistically significant) (Figures 4G, 4H, S4C, and S4D). These
results suggest that a defective HR pathway leads to an
increased number of cells accumulating DNA damage during
reprogramming. p53-mediated growth arrest and apoptosis is
responsible for the elimination of these cells and, consequently,
a significant decrease in reprogramming efficiency. Although
downregulating p53 rescues the reprogramming phenotype in
HR-deficient MEFs, it may also allow the generation of iPSCs
with genetic aberrations (Figure 4I).
DISCUSSION
Current reprogramming strategies rely on the ectopic expression
of defined sets of pluripotency-associated transcription factors
(Hochedlinger and Plath, 2009; Okita and Yamanaka, 2011).
The recent development of nonintegrative methods for intro-
ducing reprogramming genes theoretically circumvents un-
desirable genetic modifications in iPSCs caused by transgene
insertions in classic reprogramming approaches (Gonza´lez
et al., 2011). However, surveys of iPSCs generated with both
integrative and nonintegrativemethods reveal significant genetic
abnormalities (Gore et al., 2011; Hussein et al., 2011; Laurent
et al., 2011; Mayshar et al., 2010). Here, we show that ectopic
expression of reprogramming factors increases the level of the
DNA DSB marker gH2AX independently of viral integration.
This effect may be linked to oncogenic activities of reprogram-
ming factors (Daley, 2008). On the other hand, epigenetic remod-
eling, including global DNA demethylation, may also contribute
to DNA damage during reprogramming. Although the mecha-
nisms by which 5-methylcytosine is converted into cytosine in
CpG islands are not yet well understood, prevailing models
suggest that this conversion involves potentially mutagenicCell Reports 3, 651–660, March 28, 2013 ª2013 The Authors 655
Figure 3. HR Genes Are Directly Required during Reprogramming
(A–C) Representative AP staining (A) and quantification of AP+ (B) and Nanog+ (C) colonies generated with 4F reprogramming and a panel of shRNAs targeting
Brca1 (shBrca1-a, shBrca1-b, and shBrca1-c),Brca2 (shBrca1-a, shBrca1-b, and shBrca1-c), andRad51 (shRad51-a, shRad51-b, and shRad51-c) compared to
the shRNA control vector (shCtrl). Lower case letters refer to individual shRNAs targeting each HR gene. shBrca1-c, shBrca2-b, and shRad51-b were used for
further experiments.
(D) The upper panel shows representative fluorescence images of Oct4-GFP+ colonies generated with 4F and shRNAs targeting HR genes. The lower panel
shows representative AP staining images from reprogrammable (Rep.) MEFs infected with shRNAs against HR genes.
(E) Quantification of Oct4-GFP+ colonies from experiments with 4F-infected Oct4-GFP MEFs and acute HR-gene knockdown.
(F and G) Quantification of AP+ (F) and Nanog+ (G) colonies from experiments using reprogrammable MEFs and acute HR-gene knockdown.
See also Figures S2 and S3.DNA modifications that need to be processed through DNA
repair mechanisms (Teperek-Tkacz et al., 2011).
Our results show that an intact HR pathway is required for
efficient reprogramming, even in the absence of viral integration
or potential genome-modifying agents, such as the oncogene656 Cell Reports 3, 651–660, March 28, 2013 ª2013 The Authorsc-Myc. The complete loss of function of HR genes during
reprogramming may lead to even more profound effects. HR
genes may also have functions in addition to DNA repair during
reprogramming. For example, Brca1 is implicated in basal tran-
scriptional regulation (Mullan et al., 2006) and transcriptional
Figure 4. Downregulating p53 Rescues the Reprogramming Phenotype of HR-Defective MEFs
(A–C) Representative AP staining (A) and quantification of AP+ (B) and Nanog+ (C) colonies generated with 4F reprogramming from Brca2D27 homozygous mutant
and wild-type MEFs infected with an shRNA targeting p53 (shp53) or vector control (shCtrl).
(D–F) Representative AP staining (D) and quantification of AP+ (E) and Nanog+ (F) colonies generated with 4F reprogramming from p53/ and wild-type MEFs
under acute HR-gene knockdown. All staining were performed 16 days after infected cells were replated.
(G and H) Quantification of the percentage of Phospho-Histone H3+ (PH3+) (G) and Cleaved Caspase-3+ (CSP3+) (H) cells 6 days postinfection of 4F and HR gene
knockdown in p53/ mutant and wild-type MEFs.
(legend continued on next page)
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activation of several genes, including Sox2 (Kondo and Raff,
2004). These additional roles may explain the stronger reprog-
ramming phenotype observed in Brca1 mutant MEFs in com-
parison to Brca2 mutant cells. However, differences in genetic
background and/or severity of the hypomorphic alleles used in
this work may have also contributed to the phenotypic differ-
ences. Recent evidence that core components of the nucleotide
excision repair pathway act as ESC-specific transcriptional
coactivators regulating the expression of Nanog (Fong et al.,
2011) raises the interesting possibility that additional DNA repair
pathway components may also be co-opted in ESCs to maintain
pluripotency.
Finally, a better understanding of the role of DNA repair
pathways during reprogramming will contribute to the identi-
fication of safer approaches for creating iPSCs. The generation
of desired cell types for regenerative medicine can also be
achieved with the use of more direct approaches, such as
lineage reprogramming. When compared to pluripotency re-
programming, lineage reprogramming may involve less exten-
sive epigenetic remodeling, and it does not typically rely on
ectopic expression of classic oncogenes. For regenerativemedi-
cine, it will be crucial to determine whether lineage reprogram-
ming induces levels of DNA damage similar to pluripotency
reprogramming and to assess its mutagenic impact.
EXPERIMENTAL PROCEDURES
Mouse Strains
All animal experiments are approved by Institutional Animal Care and Use
Committee (IACUC) of Memorial Sloan-Kettering Cancer Center.
Reprogramming and Generation of iPSC Lines
For reprogramming experiments, passage 2 MEFs were seeded at 2 3 105
cells per well of a 6-well dish. MEFs were infected twice on the next day
with fresh viral supernatants. The day after infection, MEFs were replated at
different specified densities on irradiated MEF feeder layers and cultured in
mouse ESC media (knockout DMEM supplemented with 15% Hyclone FBS,
L-glutamine, penicillin and streptomycin, nonessential amino acids, b-mer-
captoethanol, and 1000 U/ml leukemia inhibitory factor). See Extended
Experimental Procedures for a detailed description of the reprogramming
experiments performed in this article.
Knockdown of Gene Expression with shRNAs
To knock down expression of Brca1, Brca2, and Rad51 genes, we obtained
pLKO.1-puro lentiviral vectors expressing three different shRNAs per gene
from Sigma-Aldrich (MISSION shRNA constructs). In all experiments, knock-
down efficiency was assessed by qRT-PCR analyses 6 days after infection
and compared to the expression of the corresponding gene in cells infected
with an empty pLKO.1-puro control virus (Sigma-Aldrich, SHC001) (Figures
S3D, S3E, S3G, S3H, and S4B). We used a well-characterized shRNA (MLS-
shp53) (Hemann et al., 2003) to knock down p53 expression and used the
empty vector (MLS-empty) as a control (Figure S4A).
Alkaline Phosphatase and Immunofluorescence Staining
Alkaline phosphatase (AP) staining was performedwith the use of a Vector Red
Alkaline Phosphatase Substrate Kit according to the manufacturer’s guide-
lines (Vector Laboratories, SK-5100). For nuclear immunostaining, cells were(I) Our results support a critical role of the HR pathway for efficient reprogramm
damage, which is responsible for the genetic aberrations observed in iPSC lin
increased genetic aberration (indicated by dark shaded boxes) or the elimination
See also Figure S4.
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immunofluorescence staining procedures. The following primary antibodies
were used: Nanog (Cosmo Bio, REC-RCAB0002P-F), Oct4 (Santa Cruz
Biotechnology, sc-5279), Klf4 (Santa Cruz Biotechnology, sc-20691), and
Sox2 (Santa Cruz Biotechnology, sc-17320). For SSEA1 surface marker
expression analysis, live cells were directly stained for 30 min with an
SSEA1 antibody conjugated with Alexa 488 (Santa Cruz Biotechnology,
sc-21702 AF488) in PBS with 0.2% BSA.
Proliferation and Apoptosis Immunofluorescence Analysis
For proliferation and apoptosis analyses, cells (infected on the previous day, or
not infected) were plated at 104 cells per well of a 48-well dish. Five days after
plating, cells were fixed with 4% paraformaldehyde in PBS for 10 min.
Immunofluorescence staining with the use of either a Phospho-Histone H3
(Ser10) antibody (PH3) (Cell Signaling Technology, 9701S) or a Cleaved
Caspase-3 (Asp175) antibody (CSP3) (Cell Signaling Technology, 9661S)
was performed according to standard procedures. In both cases, detection
was achieved with the use of a donkey anti-rabbit Alexa 488 secondary anti-
body (Life Technologies, A21206) combined with DAPI nuclear staining. Plates
were imaged in multiple fluorescence channels with the use of a Cellomics
ArrayScan HCS Reader (Thermo Scientific) (PH3: Objective 103, channel 1
dye XF53_386_23, channel 2 dye XF53_485_20; CSP3: Objective 103,
channel 1 dye BGRFR_386_23, channel 2 dye XF53_485_20). Automated
image analysis of PH3+ cells (nuclear staining) was performed with the use
of Target Activation BioApplication V4, whereas quantification of CSP3+
cells (cytoplasmic staining) was performed with the use of Compartmental
AnalysisV4 (Figures S4C and S4D).
Flow Cytometric Analysis of gH2AX and SSEA1
Cells were first incubated with the SSEA1 antibody conjugated with Alexa 488
(described above) for 30 min. After the washing steps, cells were fixed in 70%
ice cold ethanol and stored at 20C for up to 2 weeks. Next, cells were incu-
bated with a phospho-Histone H2A.X (Ser139) antibody (Millipore, 05-636)
followed by the Alexa 647 goat anti-mouse IgG1 secondary antibody (Life
Technologies, A21240) for gH2AX detection. Finally, cells were stained with
propidium iodide (PI) solution (PBS containing 5 mg/ml PI and 100 mg/ml RNase
A) prior to flow cytometric analysis with a Becton Dickinson FACSCalibur.
Flow Cytometric Analysis of Annexin V and SSEA1
For apoptosis assays, flow cytometry was performed on cells stained with
Annexin V–FITC (BD Pharmingen, 556547) and DAPI. In some experiments,
cells were also stained with SSEA1-APC (R&D Systems, FAB2155A). In brief,
cells were washed twice with PBS and stained with 0.5 ml of Annexin V–FITC
(or with 0.5 ml of Annexin V-FITC and 4 ul SSEA1-APC) in 100 ml binding buffer
(10 mM HEPES, [pH 7.4], 140 mM NaOH, 2.5 mM CaCl2) for 30 min at room
temperature in the dark. Next, cells were washed twice with the binding buffer
and then resuspended in a binding buffer containing 1 mg/ml DAPI. Apoptotic
cells were detected with a Beckman Coulter CyAn ADP Analyzer. Both early
apoptotic (Annexin V+, DAPI) and late apoptotic (Annexin V+, DAPI+) cells
were included in cell death quantifications.
Statistical Analysis
All values are shown as mean ± SEM. p values were calculated with the use of
a two-tailed Student’s t test; p < 0.05 (*) was considered significant.
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